Palisade Bio presents PALI-2108 Phase 1b data showing response in all five ulcerative colitis patients
PALI•
PALI•Palisade Bio said all five patients in an open-label ulcerative colitis study achieved clinical response by day seven, and two achieved clinical remission. The company targets Phase 2 primary efficacy readouts in ulcerative colitis in Q4 2027 and Crohn's disease in Q1 2028.
In a five-patient, open-label ulcerative colitis study of PALI-2108, all patients achieved clinical response by day seven and two achieved clinical remission. In a 14-day, open-label Crohn's disease study, two of five patients achieved endoscopic remission; the cohort had no serious adverse events or treatment discontinuations, and all adverse events were mild.
Palisade Bio targets a fourth-quarter 2027 Phase 2 primary efficacy readout for PALI-2108 in ulcerative colitis and a first-quarter 2028 readout in Crohn's disease.